GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair | PharmaBoardroom

GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

face
TAGS: ,

With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their own blockbuster sales. And new study results comparing Advair with not-yet-launched Anoro Ellipta could help the fledgling COPD treatment do just that.

Latest Report